Appointment of David
Scadden, M.D. and Marella
Thorell
Resignation of Regina Hodits and
Björn Odlander
PHILADELPHIA, July 1, 2024
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM)
("Carisma" or the "Company"), a clinical-stage biopharmaceutical
company focused on discovering and developing innovative
immunotherapies, today announced the appointment of Marella Thorell and David Scadden, M.D., to the Company's Board of
Directors, effective June 30, 2024.
Additionally, Regina Hodits and
Björn Odlander have informed the Board of their intention to step
down as members effective June 30,
2024, due to other professional commitments.
"We are pleased to welcome David and Marella to the Carisma
Board of Directors. Their vast experience in the life sciences
sector will be instrumental in advancing our cell therapy platform
focused on engineered macrophages," said Sanford Zweifach, Chair of the Carisma Board of
Directors. "We would also like to thank Regina and Björn for their
invaluable contributions, guidance, and leadership throughout their
tenure. We wish them the utmost success in their future
endeavors."
"Dr. Scadden's renowned expertise as a physician and medical
researcher will be incredibly valuable to Carisma, and we are
honored to welcome him to our Board of Directors. Ms. Thorell's
experience as a public company executive and Board Member of
biotech companies will enhance the business capabilities of our
Board," said Steven Kelly, President
and Chief Executive Officer of Carisma. "These new appointments
enrich our Board's diversity of experience and perspective,
providing exemplary leadership as we work with urgency to bring
groundbreaking immunotherapies to patients."
About David Scadden
Dr. Scadden is the Gerald and Darlene Jordan Professor of
Medicine and Professor of Stem Cell and Regenerative Biology at
Harvard University. Dr. Scadden founded
and directs the Center for Regenerative Medicine at Massachusetts General Hospital and co-founded and
co-directs the Harvard Stem Cell Institute. Dr. Scadden is Chairman
Emeritus and Professor of the Harvard
University Department of Stem Cell and Regenerative Biology.
Dr. Scadden has received numerous honors and awards and has served
on the board of scientific counselors for the National Cancer
Institute, the board of external experts for the National Heart,
Lung, and Blood Institute, the board of directors of the
International Society for Stem Cell Research and is an affiliate
member of the Broad Institute of Harvard and MIT. He
serves on multiple editorial boards, scientific advisory boards,
and corporate boards. He is a scientific founder of Fate
Therapeutics, Inc., and Dianthus Therapeutics, Inc., and also
serves on the Board of Directors of Agios Pharmaceuticals, Inc.,
and Editas Medicine, Inc. Dr. Scadden received a bachelor's degree
in English from Bucknell University and
an M.D. from Case Western Reserve School of Medicine.
About Marella Thorell
Marella Thorell brings more than
25 years of extensive experience in finance and operations across
both public and private biotech companies. Ms. Thorell is currently
the Chief Financial Officer of Seres Therapeutics. Previously, she
served as the Chief Financial Officer of Evelo Biosciences. Her
prior roles include Chief Accounting Officer at Centessa
Pharmaceuticals, Chief Financial Officer of Palladio Biosciences
prior to its acquisition by Centessa, and Chief Financial Officer
and Chief Operating Officer of Realm Therapeutics. Before her time
at Realm Therapeutics, Ms. Thorell held positions of increasing
responsibility at Campbell Soup Company and Ernst & Young, LLP.
Ms. Thorell is a Director and Chair of the Audit Committee of ESSA
Pharmaceuticals and was previously Chair of the Board of Vallon
Pharmaceuticals before its merger in 2023. Ms. Thorell received a
bachelor's degree in business from Lehigh
University.
About Carisma
Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical
company focused on utilizing our proprietary macrophage and
monocyte cell engineering platform to develop transformative
immunotherapies to treat cancer and other serious diseases. We have
created a comprehensive, differentiated proprietary cell therapy
platform focused on engineered macrophages and monocytes, cells
that play a crucial role in both the innate and adaptive immune
response. Carisma is headquartered in Philadelphia, PA. For more information, please
visit www.carismatx.com.
Investors:
Shveta
Dighe
Head of Investor Relations
investors@carismatx.com
Media Contact:
Julia
Stern
(763) 350-5223
jstern@realchemistry.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-announces-changes-to-its-board-of-directors-302186226.html
SOURCE Carisma Therapeutics Inc.